Investor Relations

Get stock updates, FAQs, and more.

go to Investor Relations

Our Best-in-Class Companies

Find a powerful partner that promises results.

find an inVentiv Health company

Contact Information

If you are representing a media outlet and have immediate questions, please contact:

MARCIA FREDERICK
614.543.6281
mfrederick@inventivhealth.com

Press Releases

inVentiv Health Expands into Japan

·        Establishes inVentiv Japan Operation

·        Multiple Agreements for Sales Teams

SOMERSET, N.J. - Aug 3, 2009 - inVentiv Health (NASDAQ: VTIV), a leading provider of commercialization services to the global pharmaceutical and healthcare industries, announced today it has established inVentiv Japan, a Tokyo-based operation that will provide commercialization services to healthcare clients. 

"Japan is among the largest pharmaceutical markets in the world and our clients are launching many products into the Japanese market," said Blane Walter, Chief Executive Officer of inVentiv Health Inc. "Establishing inVentiv Japan will enable us to fulfill our clients' needs, while also supporting inVentiv's growth as a global healthcare leader." 

inVentiv Japan will provide outsourced sales solutions through the company's Selling Solutions division. inVentiv currently has agreements with four top 20 pharmaceutical companies and a Japanese specialty pharmaceutical manufacturer to provide sales teams that will promote several of their products in Japan.

Japan was a $76.6 billion market for pharmaceutical sales in 2008, with expected growth of 4-5% in 2009, according to IMS data.  The market is comprised of approximately 56,000 pharmaceutical sales representatives, but only about 4% are currently outsourced.

"We believe there is significant opportunity for outsourced sales growth in Japan," said Terry Herring, President and COO of inVentiv Health Inc. "Not only have many top-selling U.S. pharmaceutical products not yet launched in Japan, but a growing number of pharmaceutical companies in Japan are looking to increase the flexibility of their workforce.  We have been extremely pleased by the initial response to our offering over the past quarter, and we are excited by the opportunity to build additional client relationships in this expanding market."

inVentiv's sales operation in Japan is led by Dan Feldman. Mr. Feldman has more than 20 years of senior management experience in marketing and sales of ethical and over-the-counter pharmaceutical products, and in the delivery of outsourced services in Japan, Asia, and Australia.  Prior to joining inVentiv, he served as Vice President of Sales at Merck-Banyu in Japan, and held several senior-level positions with pharmaceutical service providers in Japan and Korea.  Mr. Feldman also previously founded Churchill Communications, the first healthcare communications firm in Japan. 

"Dan Feldman is the ideal person to lead our sales operation in Japan. His experience managing pharmaceutical commercialization efforts in Japan and throughout Asia is unparalleled. Also, having worked for both pharmaceutical manufacturers and service providers, he brings valuable perspectives on the needs of our clients," said Thomas Dimke, Senior Vice President, overseeing international efforts for inVentiv Selling Solutions.

In addition to its Selling Solutions offering, inVentiv Health also has Communications capabilities in Japan through an affiliate relationship with Ad-comm Group, a privately-held network of specialized communications companies in Japan. 

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve known and unknown risks that may cause inVentiv Health's performance to differ materially. Such risks include, without limitation: our ability to sufficiently increase our revenues and maintain or decrease expenses and cash capital expenditures to permit us to fund our operations; our ability to continue to comply with the covenants and terms of our credit facility and to access sufficient capital to fund our operations; our ability to grow our existing client relationships, obtain new clients and cross-sell our services; our ability to successfully operate new lines of business; our ability to manage our infrastructure and resources to support our growth; our ability to successfully identify new businesses to acquire, conclude acquisition negotiations and integrate the acquired businesses into our operations; any disruptions, impairments, or malfunctions affecting software as well as excessive costs or delays that may adversely impact our continued investment in and development of software; the potential impact of government regulation on us and on our clients base; our ability to comply with all applicable laws as well as our ability to successfully implement from a timing and cost perspective any changes in applicable laws; our ability to recruit, motivate and retain qualified personnel, including sales representatives; the actual impact of the adoption of certain accounting standards; our ability to maintain technological advantages in a variety of functional areas, including sales force automation, electronic claims surveillance and patient compliance; changes in trends in the healthcare and pharmaceutical industries or in pharmaceutical outsourcing; and our inability to determine the actual time at which the liquidation of the Columbia Strategic Cash Portfolio will be completed or the total losses that we will actually realize from that investment vehicle. . Readers of this press release are referred to documents filed from time to time by inVentiv Health Inc. with the Securities and Exchange Commission for further discussion of these and other factors.